Nanobiotix (NBTX) Stock Price, News & Analysis

Company Overview

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Key Stats

• Today's Range: $3.68 to $3.94
• 50-Day Range: $2.83 to $4.16
• 52-Week Range: $2.76 to $7.51
• Volume: 6,228 shs
• Average Volume: 8,634 shs
• Market Capitalization: $176.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Moderate Buy

Nanobiotix Stock Analysis - MarketRank™

Nanobiotix scored higher than 43% of companies evaluated by MarketBeat, and ranked 653rd out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nanobiotix has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Nanobiotix has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nanobiotix are expected to grow in the coming year, from ($1.18) to ($0.86) per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.04% of the outstanding shares of Nanobiotix have been sold short.

Short Interest Ratio / Days to Cover

Nanobiotix has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nanobiotix has recently increased by 22.84%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nanobiotix does not currently pay a dividend.

Dividend Growth

Nanobiotix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.04% of the outstanding shares of Nanobiotix have been sold short.

Short Interest Ratio / Days to Cover

Nanobiotix has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nanobiotix has recently increased by 22.84%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.74

News Sentiment

Nanobiotix has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Nanobiotix this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nanobiotix insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.45% of the stock of Nanobiotix is held by insiders.

Percentage Held by Institutions

Only 38.81% of the stock of Nanobiotix is held by institutions.

NBTX Stock Analysis - Frequently Asked Questions

How have NBTX shares performed this year?

Nanobiotix's stock was trading at $2.87 at the beginning of the year. Since then, NBTX shares have increased by 30.7% and is now trading at $3.75.
View the best growth stocks for 2025 here.

When did Nanobiotix IPO?

Nanobiotix (NBTX) raised $95 million in an IPO on Friday, December 11th 2020. The company issued 6,500,000 shares at a price of $14.69 per share. Jefferies, Evercore ISI, UBS Investment Bank and Gilbert DuPont acted as the underwriters for the IPO.

Who are Nanobiotix's major shareholders?

Top institutional shareholders of Nanobiotix include OLD Mission Capital LLC (0.10%), Jane Street Group LLC (0.05%), Millennium Management LLC (0.03%) and Geode Capital Management LLC (0.02%).

How do I buy shares of Nanobiotix?

Shares of NBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nanobiotix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nanobiotix investors own include PayPal (PYPL), Sirius XM (SIRI), Ardelyx (ARDX), BridgeBio Pharma (BBIO), Cogent Communications (CCOI), Citius Pharmaceuticals (CTXR) and Datadog (DDOG).

Company Calendar

• Today: 2/22/2025
• Next Earnings (Estimated): 4/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NBTX
• CUSIP: N/A
• CIK: 1760854
• Web: www.nanobiotix.com
• Phone: 33-1-40-26-04-70
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $12.00
• High Stock Price Target: $12.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +220.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.42
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $39.18 million
• Price / Sales: 4.51
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.04) per share
• Price / Book: -93.75

Miscellaneous

• Outstanding Shares: 47,130,000
• Free Float: 45,507,000
• Market Cap: $176.74 million
• Optionable: Not Optionable
• Beta: 0.29